February 1, 2019

Gerald McMahon
Chief Executive Officer
Harpoon Therapeutics, Inc.
4000 Shoreline Court, Suite 250
South San Francisco, CA 94080

       Re: Harpoon Therapeutics, Inc.
           Amendment No. 2 to Registration Statement on Form S-1
           Filed January 29, 2019
           File No. 333-229040

Dear Mr. McMahon:

      We have reviewed your amended registration statement and have the
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
circumstances or do not believe an amendment is appropriate, please tell us why
in your

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Amendment No. 2 to Registration Statement on Form S-1

Choice of Forum, page 169

1.     Please revise your exclusive forum disclosure here and in the risk
factor section to identify
       the other courts you have selected as forums in the event the Delaware
Court of Chancery
       lacks jurisdiction.
2.     We note that your forum selection provision identifies the Court of
Chancery of the State
       of Delaware (or, if and only if the Court of Chancery of the State of
Delaware lacks
       subject matter jurisdiction, any state court located within the State of
Delaware or, if and
       only if all such state courts lack subject matter jurisdiction, the
federal district court for
       the District of Delaware) as the exclusive forum for certain litigation,
including any
       "derivative action." Please disclose whether this provision applies
solely to state law
       claims. If it does not apply solely to state law claims, Section 22 of
the Securities Act
 Gerald McMahon
Harpoon Therapeutics, Inc.
February 1, 2019
Page 2
         creates concurrent jurisdiction for federal and state courts over all
suits brought to enforce
         any duty or liability created by the Securities Act or the rules and
regulations thereunder.
         If the provision applies to Securities Act claims, please revise your
prospectus to disclose
         this information and to state that there is uncertainty as to whether
a court would enforce
         such provision, and to state that stockholders will not be deemed to
have waived the
         company's compliance with the federal securities laws and the rules
and regulations
         thereunder. If this provision is intended to apply solely to state law
claims, please also
         ensure that the exclusive forum provision in the governing documents
states this clearly.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration

       You may contact Bonnie Baynes at 202-551-4924 or Angela Connell at
202-551-3426 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Donald Field at 202-551-3680 or Dietrich King at 202-551-8071 with any

FirstName LastNameGerald McMahon                                Sincerely,
Comapany NameHarpoon Therapeutics, Inc.
                                                                Division of
Corporation Finance
February 1, 2019 Page 2                                         Office of
Healthcare & Insurance
FirstName LastName